Naveris raises $33M to detect cancer caused by human papillomavirus

Life sciences company Naveris has raised $33.4 million in an expansion of its series A financing round.

The recent funding round brings Naveris' total capital raised to $51 million. The financing will be used to advance the commercialization of Naveris' blood test tools for the early detection of cancers caused by human papillomavirus, according to the Sept. 19 Naveris news release.

The funding round was led by Gurnet Point Capital, with participation from TechU Ventures and the venture capital arm of the American Cancer Society, BrightEdge.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars